Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: Final report of Cancer and Leukemia Group B study 19901

Leukemia and Lymphoma

Volumn 50, Issue 10, 2009, Pages 1589-1596

  Byrd, John C ^a   Peterson, Bercedis L ^b   Rai, Kanti R ^c   Hurd, David ^d   Hohl, Raymond ^e   Perry, Michael C ^f   Gockerman, Jon ^b   Nattam, Sreenivasa ^g   Larson, Richard A ^h,i  

^a OHIO STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^d WAKE FOREST UNIVERSITY   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF MISSOURI   (United States)

^g Fort Wayne Oncology and Hematology Inc   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ Cancer and Leukemia Group B   (United States)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Minimal residual disease

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALLOPURINOL; ANTIBIOTIC AGENT; COTRIMOXAZOLE; DIPHENHYDRAMINE; FLUDARABINE; GANCICLOVIR; PARACETAMOL;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DESQUAMATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HERPES; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOTENSION; INFECTION; INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT COMPLIANCE; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; BONE MARROW DISEASES; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; FEASIBILITY STUDIES; FEMALE; GLYCOPROTEINS; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM PROTEINS; SURVIVAL ANALYSIS; VIDARABINE;

EID: 70350749633     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903150839     Document Type: Article

References (27)

1. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007. Available from: http:// seer.cancer.gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site.
2. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French co-operative group on chronic lymphocytic leukemia. N Engl J Med 1998;338:1506-1514.
3. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomised controlled trial. Lancet 2007;370:230-239.
4. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol 2007;25:793-798.
5. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-891.
6. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and OS in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.
7. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088. (Pubitemid 46211313)
8. Hulkkonen J, Vilpo L, Hurme M, et al. Surface antigen expression in chronic lymphocytic leukemia: Clustering analysis, interrelationships and effects of chromosomal abnormalities. Leukemia 2002;16:178-185.
9. Gong JZ, Lagoo AS, Peters D, et al. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol 2001;116:893-897.
10. Smolewski P, Szmigielska-Kaplon A, Cebula B, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005;46:87-100.
11. Mone AP, Cheney C, Banks AL, et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006;20:272-279.
12. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002;99:3554-3561.
13. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-3897.
14. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24:2337-2342.
15. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission -experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004;18:1093-1101.
16. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98: 2657-2663.
17. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
18. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757.
19. O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008;111:1816-1819.
20. Byrd JC, Smith L, Hackbarth ML, et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003;63: 36-38.
21. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006;24:437-443.
22. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US intergroup phase III trial E2997. J Clin Oncol 2007;25:799-804.
23. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85: 1580-1589.
24. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001;115:854-861.
25. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
26. Kiaii S, Choudhury A, Mozaffari F, et al. Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment. Leuk Lymphoma 2006;47: 1229-1238.
27. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004;18:484-490.